Chiasma (CHMA) Stock Price, News & Analysis

Company Overview

Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.

Key Stats

• Today's Range: $3.76 to $3.76
• 50-Day Range: $3.76 to $4.71
• 52-Week Range: $2.77 to $5.74
• Volume: 147 shs
• Average Volume: 2.12 million shs
• Market Capitalization: $217.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CHMA Stock Analysis - Frequently Asked Questions

How were Chiasma's earnings last quarter?

Chiasma, Inc. (NASDAQ:CHMA) posted its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.18. The biotechnology company had revenue of $1.92 million for the quarter, compared to analysts' expectations of $1.80 million.

When did Chiasma IPO?

Chiasma (CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

What other stocks do shareholders of Chiasma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Cos (BHC), Meta Platforms (META), GW Pharmaceuticals (GWPH), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX) and TherapeuticsMD (TXMD).

Company Calendar

• Last Earnings: 5/06/2021
• Today: 7/18/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CHMA
• CIK: 1339469
• Web: www.chiasmapharma.com
• Phone: 617-928-5300
• Fax: N/A
• Employees: 85
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.78 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -113.57%
• Return on Assets: -57.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.91
• Quick Ratio: 7.08

Sales & Book Value

• Annual Sales: $1.11 million
• Price / Sales: 196.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.59 per share
• Price / Book: 2.36

Miscellaneous

• Outstanding Shares: 57,894,000
• Free Float: N/A
• Market Cap: $217.68 million
• Optionable: Not Optionable
• Beta: 1.28